De novo posttransplant membranous nephropathy following BNT162b2 mRNA COVID-19 vaccine in a kidney transplant recipient

Nathalie Chavarot; Michael Padden; Lucile Amrouche; Stéphanie Malard; Anne Scemla; Rebecca Sberro-Soussan; Juliette Léon; Christophe Legendre; Jean Paul Duong; Julien Zuber; Dany Anglicheau; Marion Rabant; Pierre Isnard

doi:10.1111/ajt.17166

De novo posttransplant membranous nephropathy following BNT162b2 mRNA COVID-19 vaccine in a kidney transplant recipient

Am J Transplant. 2022 Dec;22(12):3188-3189. doi: 10.1111/ajt.17166. Epub 2022 Aug 24.

Authors

Nathalie Chavarot^{1

2

3}, Michael Padden^{1

2

3}, Lucile Amrouche^{1

2

3}, Stéphanie Malard⁴, Anne Scemla^{1

2

3}, Rebecca Sberro-Soussan^{1

2

3}, Juliette Léon^{1

2

3}, Christophe Legendre^{1

2

3}, Jean Paul Duong^{3

5}, Julien Zuber^{1

2

3}, Dany Anglicheau^{1

2

3}, Marion Rabant^{3

5}, Pierre Isnard^{3

5}

Affiliations

¹ Department of Kidney and Metabolic diseases, Transplantation, and Clinical Immunology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
² Department of Immunology, Harvard Medical School, Boston, Massachusetts, USA.
³ Université de Paris, Paris, France.
⁴ Laboratoire Régional d'Histocompatibilité, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁵ Department of Pathology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

No abstract available

Publication types

Letter

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines* / adverse effects
COVID-19* / epidemiology
COVID-19* / prevention & control
Glomerulonephritis, Membranous* / etiology
Humans
Kidney Transplantation* / adverse effects
RNA, Messenger

Substances

BNT162 Vaccine
COVID-19 Vaccines
RNA, Messenger